NSABB Teleconference Meeting
This meeting will be a conference call only; there will be no in-person meeting. To join the call as a member of the public, please use the dial-in information below. The toll-free teleconference line will be open to the public at 1:30 P.M. to allow time for operator-assisted check-in. Members of the public planning to participate in the teleconference may also pre-register online. Pre-registration will close at 12:00 p.m. Eastern on May 8, 2017. After that time, attendees may register their information with the teleconference operator upon dialing into the meeting. Individuals who plan to participate and need special assistance should submit a request to the contact person listed on this notice by May 3, 2017. The agenda and other meeting material will be posted to the meeting and registration web site as they become available
Conference Line (Public): 1-866-939-3921
Time will be allotted on the agenda for the delivery of oral public comments. Members of the public interested in delivering prepared comments relevant to the mission of the NSABB should indicate so upon registration. Sign-up for delivering prepared oral comments will be limited to one per person or organization representative per open comment period. Individual comments will be time-limited to facilitate broad participation from multiple speakers.
In addition, interested persons may file written comments at any time with the Board via an email sent to email@example.com or by regular mail sent to the Contact Person listed below. Written statements should include the name, contact information, and when applicable, the professional affiliation of the interested person. Written comments received by 12:00 p.m. Eastern on May 8, 2017 will be relayed to the NSABB prior to the teleconference meeting. Any written comments received after this deadline will be provided to the Board either before or after the meeting, depending on the volume of comments received and the time required to process them in accordance with privacy regulations and other applicable federal policies.
Additional questions please contact:
Office of Science Policy
National Institutes of Health
6705 Rockledge Drive, Suite 750
Bethesda, Maryland 20892